United Therapeutics Corporation
UTHRNASDAQHealthcare● Active
$550.43
+$0.56(+0.10%)
Market Cap$23.4B
P/E Ratio—
52W High$609.35
52W Low$272.12
United Therapeutics Corporation (UTHR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · UTHR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Cost of Revenue | $0.38B | $0.31B | $0.26B | $0.15B | $0.12B |
| Gross Profit | $2.80B | $2.57B | $2.07B | $1.79B | $1.56B |
| Gross Margin %(computed) | 87.92% | 89.24% | 88.94% | 92.42% | 92.73% |
| Operating Expenses | |||||
| R&D Expenses | $0.55B | $0.48B | $0.41B | $0.32B | $0.54B |
| G&A Expenses | $0.61B | $0.54B | $0.40B | $0.42B | $0.40B |
| Total Operating Expenses | $1.28B | $1.19B | $0.89B | $0.81B | $1.01B |
| Operating Income | $1.52B | $1.38B | $1.18B | $0.98B | $0.56B |
| Operating Margin %(computed) | 47.67% | 47.86% | 50.91% | 50.60% | 32.98% |
| Interest Income | $0.19B | $0.20B | $0.16B | $0.05B | $0.02B |
| Interest Expense | $0.02B | $0.04B | $0.06B | $0.03B | $0.02B |
| Income Before Tax | $1.71B | $1.54B | $1.27B | $0.95B | $0.59B |
| Income Tax Expense | $0.38B | $0.34B | $0.29B | $0.22B | $0.12B |
| Net Income | $1.33B | $1.20B | $0.98B | $0.73B | $0.48B |
| Net Margin %(computed) | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $30.13 | $26.44 | $21.04 | $15.98 | $10.60 |
| Wtd Avg Shares | 0.04B | 0.05B | 0.05B | 0.05B | 0.04B |
| EBITDA | $1.82B | $1.65B | $1.39B | $1.04B | $0.74B |
| EBITDA Margin %(computed) | 57.15% | 57.50% | 59.58% | 53.73% | 43.71% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more United Therapeutics Corporation data
About United Therapeutics Corporation (UTHR) Income Statement
United Therapeutics Corporation (UTHR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, UTHR reported revenue of $3.18B, gross profit of $2.80B (gross margin 87.92%), and net income of $1.33B — a net profit margin of 41.94%.
Frequently asked questions
UTHR · 4 questionsUnited Therapeutics Corporation (UTHR) reported revenue of $3.18B for 2025, up 10.6% year-over-year.
UTHR revenueUTHR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08